Clinical Trial Update: AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating AST-120 (Kremezin) for renal protection and attenuation of decline in acute kidney disease or acute kidney injury is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Disease
• Kidney Injury

Drugs mentioned

• Kremezin (AST-120)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Acute Kidney Disease, Acute Kidney Injury (AKI) | Phase 4 | Status: RECRUITING